Understand the source comparison
Leaky Gut Peptides 2026 Update: Comparison of Research Compounds
BPC-157 VEGFR2 activation, tight junction upregulation SC injection or oral (enteric) 250–500 mcg SC daily or 500–1000 mcg oral Increased occludin/ZO-1 by 34–47% in 72 hours Most versatile. Both mucosal healing and junction repair Thymosin Beta-4 Actin stabili
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- VEGFR2 activation, tight junction upregulation
- SC injection or oral (enteric)
- 250–500 mcg SC daily or 500–1000 mcg oral
- Increased occludin/ZO-1 by 34–47% in 72 hours
- Most versatile. Both mucosal healing and junction repair
- Thymosin Beta-4
- Actin stabilisation, epithelial restitution
- SC injection
- 2–5 mg twice weekly
- Reduced permeability by 29% in UC patients
- Strong for inflammatory bowel conditions
- KPV
- NF-κB inhibition, anti-inflammatory
- SC injection or liposomal oral
- 500 mcg–2 mg daily
- Reduced LPS-induced permeability by 53% in vitro
- Best for cytokine-driven barrier dysfunction
- Larazotide Acetate
- Zonulin receptor antagonist
- Oral (investigational drug)
- 0.5–2 mg three times daily
- 15–20% reduction in gluten-induced permeability
- Narrow application. Celiac and gluten sensitivity
- LL-37
- Antimicrobial, tight junction modulation
- SC injection or topical mucosal
- 2–10 mg weekly
- 62% reduction in bacterial translocation in vitro
- Dual benefit for dysbiosis and barrier integrity